SOGUG-NEOWIN: A phase 2, open-label, multicenter, multinational interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and the combination of ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) harboring FGFR gene alterations.

Authors: Guillermo de Velasco, Andrea Necchi, Yohann Loriot, Syed A. Hussain

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4628

Source: Full article

TPS4628